First line treatment options for activating EGFR non-small cell lung Cancer | Dr. Alexander Spira

Current and Future Management of Non-Small Cell Lung Cancer with an EGFR MutationПодробнее

First Line EGFR Based Therapy For Advanced Squamous Non Small Cell Lung Cancer NSCLCПодробнее

Dr. Alexander Spira Discusses Advances in Non-Small Cell Lung Cancer (NSCLC)Подробнее

ESMO 2023 Lung Cancer - Chapter 2 Highlights – PAPILLON, MARIPOSA, MARIPOSA-2, LIBRETTO-431Подробнее

Current and Future Management of Non-Small Cell Lung Cancer with an EGFR MutationПодробнее

NSCLC: Integrating EGFR-Inhibiting Therapies into Clinical Pathways for First-Line TreatmentПодробнее

What I Tell My Patients: Non-Small Cell CancerПодробнее

Second line treatment in activating EGFR non-small cell lung cancer, MARIPOSA - 2 | Onc BrothersПодробнее

Developments and challenges in MET targeting for lung cancerПодробнее

New Standard of care Treatment for EGFR Exon 20 Non-small cell Lung Cancer | Dr. Alexander SpiraПодробнее

Dr. Massarelli on First-Line ALK + NSCLC TreatmentПодробнее

Treatment Options for EGFR-positive Lung CancerПодробнее

Frontline Treatment for EGFR+ NSCLCПодробнее

The Changing Landscape of First Line Treatment for EGFR Mutation-Positive NSCLC.Подробнее

PD-L1 testing in first-line treatment of NSCLCПодробнее

Treatment Options: Newly Diagnosed EGFR+ NSCLCПодробнее

Alex Spira, MD, PhD, FACP, discusses the mechanism of action of amivantamab (JNJ-6372)Подробнее

Dr. Spira on the POPLAR Study for NSCLCПодробнее

METalmark: amivantamab and capmatinib in advanced NSCLCПодробнее

Immunotherapy Treatments for Non-Small Cell Lung Cancer (NSCLC)Подробнее

First Line Treatment of EGFR Mutation-Positive NSCLCПодробнее

Osimertinib for treating non-small cell lung cancerПодробнее